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Abstract
Background: Recruitment to randomised controlled trials with children is challenging. It is imperative to understand
the factors that boost or hinder recruitment of children to clinical trials. We conducted a survey of facilitators and
barriers to recruitment to the MAGNETIC trial, using a previously developed web-based tool.
Methods: MAGNETIC is a multicentre randomised trial of nebulised magnesium in acute severe asthma,
recruiting 508 children from 30 UK sites. Recruiters were asked to grade a list of factors from –3 to +3
depending on whether the factor was perceived as a strong, intermediate or weak barrier (–3 to –1) or
facilitator (+1 to + 3), and using (0) if it was thought to be not applicable. Free text responses were invited
on strategies applied to counter the identified barriers.
Results: The commonly identified facilitators were motivation and experience of study teams, effective
communication and coordination between teams at site and between sites and the Clinical Trials Unit, the
presence of designated research nurses, good trial management, clinical trial publicity, simple inclusion criteria,
effective communication with parents and presentation of trial information in a simple and clear manner. The
commonly identified barriers were heavy clinical workload, shift patterns of work, Good Clinical Practice (GCP)
training, inadequate number of trained staff, time and setting of consent seeking, non-availability of research
staff out of hours and parents' concerns about their child taking an experimental medicine. Having a
designated research nurse, arranging GCP training and trial-related training sessions for staff were the most
commonly reported interventions.
Conclusions: This study highlights important generic and trial-specific facilitators and barriers to recruitment
to a paediatric trial in the acute setting and provides information on the recruitment strategies or
interventions that were applied to overcome these barriers. This information can be very useful in informing
the design and conduct of future clinical trials with children, particularly in the acute or emergency setting.
Trial registration: ISRCTN, ISRCTN81456894. Registered on 15 November 2007.
Keywords: Recruitment, Children, Clinical trials, RCT (randomised controlled trial), Survey
Background
Conducting clinical trials with children is challen-
ging. Protection from harm due to an intervention
and obtaining consent or assent are particular chal-
lenges in paediatric studies [1, 2]. Recruiting ad-
equate numbers of eligible participants is crucial for
successful completion of a trial. Poor recruitment
impacts the validity of study findings, is a common
cause of requests for trial extensions and may result
in premature termination of trials [3–5]. Recruitment
to a randomised controlled trial can be affected by
many internal and external factors. Understanding
how these factors influence the success or failure of
large multicentre studies and how clinical teams
overcome them will improve the planning, design
and conduct of future clinical trials [4]. We con-
ducted a survey from all those sites that contributed
to recruitment to a large multicentre study examin-
ing nebulised magnesium sulphate in acute asthma
in children (the MAGNETIC study) [6]. The aim
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was to explore the facilitators and barriers to
recruitment during that study.
Methods
Setting
The MAGNETIC trial was a randomised, multicentre,
double-blind, placebo-controlled trial evaluating the
role of nebulised magnesium in severe acute asthma
in children unresponsive to standard inhaled
treatment. Children aged from 2 to 16 years old, pre-
senting to an emergency department or children’s as-
sessment unit with acute severe asthma were given
conventional treatment on presentation and reas-
sessed after 20 minutes; those fulfilling the eligibility
criteria were enrolled into the study. Written in-
formed consent was obtained from parents or guard-
ians in the 20-minute period when the child was
receiving initial treatment [6].
The trial recruited successfully to target, enrolling
508 children from 30 sites across the UK, needing a
short extension of 3 months beyond the planned re-
cruitment period of 24 months. Despite the overall
success of the trial, the recruitment experience at
sites was variable. The sites were a mix of tertiary
children’s hospitals with paediatric intensive care unit
(PICU ) with extensive paediatric research experience
(40%); medium (34%) and large (23%) district general
hospitals with no PICU and minimal research experi-
ence; and large general hospitals with extensive re-
search experience but less paediatric research
experience (3%). There were three additional sites
which had opened but could not recruit any patients
and a further four where efforts were made to set up
the trial but they did not open to recruitment. We
conducted a survey of recruitment experience of clin-
ical teams at all sites to explore their views on facili-
tators and barriers to recruitment and gather
information on various interventions that were ap-
plied to overcome the hurdles that were identified at
each site.
Tool used
The survey was conducted using a previously devel-
oped, web-based recruitment survey tool which pro-
vides an evidence-based, comprehensive list of
potential facilitators and barriers [7], using online sur-
vey software (www.surveygizmo.com). The survey
questionnaire was divided into three sections to col-
lect information on:
1. Responder characteristics such as name of site, study
role and duration and period of involvement in the trial
2. Perception of clinical teams with regard to
facilitators and barriers to recruitment
3. Recruitment strategies or interventions that were
applied at various sites to improve recruitment.
The perception of clinical teams with regard to facili-
tators and barriers to recruitment was assessed by asking
the responders to score a preformed, evidence-based list
of potential factors that affected recruitment to clinical
trials [7]. These factors were categorised in terms of
operating at the level of trial, site, patient, clinical team,
information and consent process and central study team.
The responders were asked to grade each factor from
–3 to +3 depending on whether the factor was perceived
as a strong (–3), intermediate (–2) or weak (–1) barrier,
or a weak (+1), intermediate (+2) or strong (+3) facilita-
tor or (0) if the factor was thought to be not applicable.
Open questions were asked to gather information on in-
terventions and strategies applied by clinical teams to
counter the problems that were identified at the sites
(see the Appendix, Table 5).
Who was asked?
The survey was conducted from August 2011 to
February 2012, following completion of trial recruit-
ment at all sites. Permission to contact the clinical
staff was obtained from the Principal Investigator (PI)
at each site, following which their contact details were
requested from the National Institute of Health
Research (NIHR) Medicines for Children Research
Network (MCRN) Clinical Trials Unit, which was re-
sponsible for coordinating the trial. The link to the
online survey was emailed to clinical teams involved
with recruitment to the trial. The list of available
contacts consisted of medical and nursing staff
delegated to recruit to the trial. This included the
PIs, research nurses, medical practitioners, nurse
practitioners and nursing staff. No formal sample size
calculation was done. The survey questionnaire was
emailed to all available contacts, but extra efforts
were made to obtain responses from PIs and at least
one research nurse at each site. This was done to
gather the views of a stable research team engaged
with recruitment at each site, as trainee doctors and
nurses were expected to change over and move be-
tween hospitals over the 2-year study recruitment
period.
An initial invitation describing the aims of the sur-
vey provided the link for completion. Voluntary par-
ticipation was requested, and potential responders
were reassured that no personal information would be
collected, no sites would be identified in any publica-
tion and confidentiality of data would be maintained.
The non-responders were sent two subsequent email
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reminders spaced 4 weeks apart. The PIs and research
nurses were sent additional email reminders followed
by a telephone reminder.
Commonly identified facilitators and barriers were
defined a priori as those that were identified as a fa-
cilitator or barrier by 50% or more of the responders.
Responders who scored a factor as –1, –2 or –3 were
aggregated to give the total number of responders
who identified the factor as a barrier. Similarly, re-
sponders who scored a factor as +1, +2 or +3 were
added to give the total number of responders who
identified the factor as a facilitator. In addition to the
overall responses, the PI and research nurse responses
were analysed separately, and the total number of re-
sponders who identified the factor as facilitator or
barrier or not applicable were calculated in a similar
manner. One PI and one research nurse response per
site, chosen at random, were included in the analysis
to ensure equal representation of sites. The free text
responses on recruitment strategies were grouped into
recurring themes using the NVivo 10 qualitative data
package.
Results
A list of 656 potential contacts was obtained from
the study delegation log of which contact details
could be obtained for 491. This included PIs and re-
search nurses at all 37 sites and other clinical staff at
30 of the 33 open sites; permission to contact other
staff could not be obtained from the PIs at the
remaining 3 sites.
A total of 206 responses were received: 169
complete and 37 partial responses. Of the 37 partial
responses, 14 were duplicate responses, no data were
recorded in 20 and less than 25% of the questions
were answered in 3. These were excluded from ana-
lysis. The number and percentage of overall responses
by role, duration and period of involvement are
shown in Table 1. The overall response rate to the
survey was 39%; 192 of 491 responses were received
after excluding the duplicate responses. The response
rates for PIs and at least one research nurse per site
are presented in Table 2. Each site was represented
by the PI and research nurse. The commonly identi-
fied facilitators and barriers to recruitment identified
in overall responses are ranked in order of frequency
and presented in Table 3.
Facilitators of recruitment
Motivation and commitment of the study team was
the most commonly identified facilitator to trial re-
cruitment (78.9%). Effective communication and co-
ordination between study team members at the site
(74.5%) and between the site and the Clinical Trials
Unit (CTU) were also recognised to be very import-
ant. The presence of a research nurse (68.1%) and
having a designated research team (58.4%) were
thought to be very helpful in assisting busy clinical
teams with trial recruitment and data collection. An
experienced Principal Investigator (PI) (63.3%) and an
enthusiastic clinical team with good communication
skills (70.3%) were thought to be instrumental in re-
solving local issues and ensuring successful trial re-
cruitment at sites. The clinical team’s perception of
the importance of the research question (60.1%) and
a positive attitude to involving patients in research
(60.9%) were felt to be very important. Encourage-
ment and support provided by PIs, senior clinicians
and research nurses was important to keep up the
motivation levels of staff and develop a positive re-
search culture. Trial management support (62%) and
effective communication between the CTU and study
teams at sites (62.1%) were recognised as facilitators.
Internal trial publicity by the study teams (62.9%)
helped to maintain the presence of the MAGNETIC
trial among teams and increase parents’ and families’
awareness about the trial. Simple patient inclusion
criteria (57.5%) and clear presentation of trial infor-
mation (58.4%) boosted recruitment. Good communi-
cation between research teams and parents (50.1%)
and consent seeking by experienced and trained clini-
cians (50.4%) were thought to be very helpful in over-
coming barriers such as parental anxiety about the
Table 1 Number (%) of responses by role, duration and period
of involvement
n %
Role (n = 169)
PIs 33 19.5
Medical practitioners 71 42
Research nurses 42 24.9
Othersa 23 13.6
Duration of involvement (n = 169)
Whole trial period 92 54.4
Part of trial periodb 75 44.4
No response 2 1.2
bPeriod of involvement (n = 75)
Set-up/early recruitment period 14 18.7
Once trial established at site 54 72
Both 3 4
No response 4 5.3
aOthers included staff nurses on ward, day units and accident and emergency
departments, paediatric nurse practioners and nurse manager
bPeriod of involvement for responders who were not involved for the whole
trial period
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potential adverse effects of the trial drug and their
child taking an experimental medication or placebo.
Barriers to recruitment
Parents’ concerns about side effects (65.3%) and their at-
titude towards their child taking experimental medicine
or placebo (57.2%) were recognised as important bar-
riers. Clinical teams expressed discomfort in ap-
proaching patients to seek consent (53.9%). Excessive
amounts and complexity of trial information and the
time taken to complete trial-related administrative work
were criticised (66.6%). Additionally, language and cul-
tural barriers were thought to hinder recruitment
(50.3%). Recruitment difficulties arising due to seasonal
variation were also recognised (51.8%).
Heavy clinical workloads (87.3%), shift patterns of
work (77.7%) and a lack of adequate trained staff mem-
bers (77.3%) were the most commonly recognised
barriers. Lack of availability of research staff to help with
recruitment, particularly during busy times and out of
hours (57%), was recognised as an important barrier, as
these were noted to be times with excess patient flow
but reduced staff, which resulted in missing out on
eligible participants for recruitment.
An important regulatory hurdle identified by a high
proportion of responders was Good Clinical Practice
(GCP) training for clinical staff (69.6%). Arranging
GCP training and encouraging clinical staff to attend
was found to be very difficult. Rapid turnover of doc-
tors and shift patterns of work made it difficult to
have GCP-trained staff in every shift, again hindering
recruitment of eligible patients.
The time and setting of consent seeking was identi-
fied as an important barrier (76%). There was a 20-
minute window period for taking informed consent
while the patient was receiving initial treatment in
Table 2 Response rates for PIs and at least one research nurse per site
Sites Number of PIs PI responses Number of research nurses RN responses
(one per site)
Sites that recruited (n = 30) 29* 27 (93%) 28 α 28 (100%)
Sites that opened but didn’t recruit (n = 3) 3 3 (100%) 1 α, β 1 (100%)
Sites that never opened (n = 4) 4 2 (50%) 1 β 1 (100%)
*PI at one site on maternity leave
α RN had left post before the survey was conducted
β No designated research nurse at site
Table 3 Facilitators and barriers to recruitment in order of frequency of responses
Facilitators n (%) Barriers n (%)
Motivation of MAGNETIC study team at site 131 (78.9) Clinical workload 146 (87.3)
Communication and coordination between study team
members at site
123 (74.5) Shift patterns of work 129 (77.7)
Communication skills of clinical team 116 (70.3) Number of trained staff 130 (77.3)
Presence of designated research nurse/practitioner 113 (68.1) Time and setting of consent seeking 127 (76)
Research experience of PI and study team members at site 105 (63.3) GCP training 116 (69.6)
Publicity by the trial team 103 (62.9) Time to complete administrative work related to the trial 112 (66.6)
Communication and coordination between study team at site
and Clinical Trials Unit (CTU)
103 (62.1) Parents’ concerns about side effects of new drug 109 (65.3)
Trial management 101 (62) Parents’ attitude towards their child taking experimental
medicine or placebo
95 (57.2)
Clinician attitude to involving patients in research 101 (60.9) Availability of research staff out of hours 95 (57)
Perceived importance of the particular research question 99 (60.1) Difficulty in approaching patients for consent 90 (53.9)
Availability of designated research team 97 (58.4) Local clinical arrangements 86 (52.1)
Clarity in presentation of trial information 97 (58.4) Seasonal variation 86 (51.8)
Patient inclusion criteria 96 (57.5) Language or cultural barriers 84 (50.3)
Motivation of clinical team 89 (53.6) Amount and complexity of trial information provided 83 (50)
Experience and training of clinical team seeking consent 84 (50.4)
Communication between research team and parents 83 (50.1)
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the emergency department or children’s assessment
unit. Seeking consent from the parents of an ill child
in an acute or emergency setting in 20 minutes was
found to be very challenging by the clinical teams.
Local clinical arrangements and choice of recruitment
setting (52.1%) were highlighted as barriers; some
sites recruiting from the paediatric wards reported
that patients were not eligible for recruitment by the
time they reached the ward and suggested recruiting
patients in the accident and emergency department.
Perceptions of PIs and research nurses with regard to
facilitators and barriers to recruitment
The responses from the PIs and the research nurses
were also analysed separately. The perceptions of PIs
were different from those of research nurses and from
overall responses in some respects. Motivation of the
clinical team, their experience and training in provid-
ing information and seeking consent and communica-
tion between research team and parents were not
recognised as facilitators by PIs. However, research
experience of the clinical team was thought to boost
recruitment.
The PIs did not see parents’ concerns about side ef-
fects of the drug or their anxiety related to their child
taking experimental medicine as barriers, which may
be explained by their experience and skills in commu-
nicating with parents. This group also did not find it
difficult to approach patients for consent. Language
and cultural barriers were not perceived to be import-
ant, and information provided to parents or families
was not felt to be excessive or too complex. This
group regarded consent seeking by senior doctors and
nurses as a hindrance to recruitment.
The perceptions of research nurses were also differ-
ent in some respects, compared to overall responses
and PI responses. They recognised some additional
factors as facilitators such as the presence of clinical
equipoise, which was not identified in overall re-
sponses or by the PIs. This group perceived that re-
cruitment was better if senior doctors and nurses
sought consent. They also identified some additional
barriers. The clinical team was thought to be lacking
in research experience and motivation, which hin-
dered recruitment. Research was not perceived to be
important in routine clinical practice, and the local
research culture was felt to be unhelpful. They identi-
fied additional practical constraints such as data col-
lection and trial demands resulting from the study
protocol being different from routine clinical practice.
They felt that recruitment was hindered because
MAGNETIC was a drug trial and parents were not
familiar with the experimental medicine, resulting in
a low consent rate.
There were also differences in opinion between PIs
and research nurses in some of the domains as to
whether they were facilitators or barriers. In 15 sites
(55%) there was a difference of perception as to the
impact of the experience of the research team on
study success. Fifty-three percent of PIs perceived this
as a facilitator, whereas 77% of the research nurses
regarded this as a barrier. In 12 sites (46%) there was
a difference in perception of the impact of senior cli-
nicians and nurses seeking consent on ease of recruit-
ment. Fifty-eight percent of PIs regarded this as a
barrier, whereas 77% of the research nurses regarded
this as a facilitator.
Recruitment strategies or interventions that were applied
at sites to improve recruitment
Free text responses were received from 108 partici-
pants on interventions or strategies that were applied
to overcome the barriers to recruitment. The number
and percentage of responders who identified each of
the listed recruitment strategies are presented in
Table 4. Having a designated research nurse was the
most commonly reported intervention. Research
nurses were found to be very helpful in all stages of
recruitment, providing hands-on support to busy clin-
ical teams, encouraging staff to participate and pro-
viding training. They were thought to be instrumental
Table 4 Recruitment strategies
Recruitment strategy n (%)
Having a designated research nurse 27 (25)
Arranging GCP training and encouraging staff
to attend
22 (20.4)
Trial-related teaching and training of staff 21 (19.4)
Trial publicity 11 (10.2)
Motivation and support provided by PIs and
senior medical team
11 (10.2)
Regular communication and meetings with staff 9 (8.3)
Measures to improve availability of staff to recruit 5 (4.6)
Additional support during out of hours; extra
staff, twilight nurses
5 (4.6)
Encouraging staff to be more involved in the trial 5 (4.6)
Repeated reminders to clinical staff 5 (4.6)
Clinical Trials Unit (CTU) support and
involvement of trial coordinator
4 (3.7)
Incentives offered to staff 4 (3.7)
Nurse consent and prescribing 3 (2.7)
Simpler trial instructions and simpler paperwork 3 (2.7)
Weekly screening and ‘chasing’ medical staff
for eligible patients missed
2 (1.9)
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in bringing about a change in culture at sites and
were described as ‘critical’, ‘essential to the success of
the trial’ and ‘very effective’. One site attributed its
success to appointment of a paediatric research nurse
who was described to have ‘generated enthusiasm in
the clinical team’ and ‘made protocol violations ex-
tremely unlikely through education and reminders’,
leading to a ‘dramatic improvement in recruitment’.
Arranging GCP training was the second most com-
monly reported strategy and was reported to be very
effective. However, it was found to be challenging,
‘hard to maintain’ and difficult to train all doctors
due to practical constraints such as heavy workloads,
short-term sickness and a high rate of doctor turn-
over. Other interventions included teaching and train-
ing of staff and trial publicity measures, e.g. putting
up posters and ‘aide memoires’ such as ‘Got a
wheeze? Think MAGNETIC’. Motivation and support
provided by senior medical staff, senior staff being
available to help, regular reminders to staff, improved
availability of doctors and nurses and additional sup-
port measures during out of hours, such as extra staff
and twilight nurses and having adequate funding to
support these measures, were all considered to be
very helpful.
Recruitment and consent by senior and more expe-
rienced members of the team was felt to be very im-
portant, as ‘seeking consent in the acute setting
where treatment needs to be initiated ASAP (as soon
as possible)’ was thought to ‘put parents and clinical
teams under pressure’. CTU support, having a dedi-
cated trial manager and good relationships and effect-
ive communications between teams were found to be
very effective. Other reported interventions included
shorter and simpler trial instructions, simpler paper-
work, reduced data collection and weekly screening
and ‘chasing’ of medical staff for missing eligible
patients.
Discussion
The study findings endorse the various facilitators and
barriers to recruitment to clinical trials that have been
identified in the existing literature. Motivation of the
clinical team, good communication skills, research ex-
perience of the PI and clinical team, good trial man-
agement, research nurse support, a positive research
culture and effective communication between teams
and with patients have been recognised as important
factors that boost recruitment [4]. Time constraints of
clinicians, heavy clinical workloads, shift patterns and
training and staffing issues have been recognised as
important hindrances to recruitment [8].
The clinical teams recognised parents’ apprehension
about their child taking an experimental medicine
and their concerns about the potential adverse effects
as barriers, which have been previously described as
important considerations for parents when deciding
for their child to participate in clinical trials [9]. Pae-
diatricians have been found to consider trial participa-
tion as an additional burden for parents. This is
similar to the perception of clinical teams in our
study who expressed discomfort in approaching pa-
tients for research [9], thereby reiterating the need
for mentoring and providing training and support to
clinical staff. An excess amount and complexity of
trial information provided in the patient information
leaflets has been previously criticised, similar to the
findings in this survey.
This study highlights research nurse support and
the presence of designated research teams, particularly
out of hours, as very important. Another factor to
note is GCP training, which has been described as a
‘massive hurdle’. Engaging doctors to undertake GCP
training was found to be very difficult and described
as ‘time consuming, boring and not a priority for
busy clinicians’. The study also found some differ-
ences in the perceptions of PIs and research nurses
with regard to certain facilitators and barriers to re-
cruitment. This highlights the need to consider vary-
ing viewpoints within a research team so that
appropriate measures can be taken to facilitate re-
cruitment, and may be useful to bear in mind when
planning future trials.
An important trial-specific barrier was seeking con-
sent from the parents of an ill child in 20 minutes,
which raises the issue of an option of deferred con-
sent being available for paediatric trials in acute or
emergency settings. The UK law incorporates a de-
ferred consent process in emergency situations for
minors [10] when treatment is required urgently, ur-
gent action is required for the purposes of the trial,
consent cannot be obtained prospectively and the
procedure has been approved by the ethics commit-
tee. Deferred consent has been successfully used in a
recent randomised controlled trial evaluating the role
of impregnated central venous catheters (impregnated
with antibiotics or with heparin) or a standard central
venous catheter for prevention of blood stream infec-
tions in children (the CATCH trial) [11]. For children
needing a central venous catheter placement as an
emergency, a written parental consent was sought
after randomisation to avoid delay in treatment. A
postal survey [12] investigating parents’ views about
deferred consent in a paediatric emergency setting
showed that the majority of parents found it accept-
able. However, the death of a child during a trial in
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which deferred consent has been used presents a
complex situation. The authors highlight the need for
further evidence to guide appropriate management in
these cases.
This study highlights several important factors that
affect recruitment to clinical trials. The strengths of our
study include an electronic survey design, use of a com-
prehensive, evidence-based recruitment survey tool, a
wide range of responders with different roles from sites
with variable recruitment performance and a good repre-
sentation of sites with high response rates from PIs and
research nurses at each site. E-surveys are quicker, less ex-
pensive, can be sent to multiple responders at the same
time, avoid interviewer bias and allow the responders to
express their views freely and anonymously, even regard-
ing sensitive issues [13].
Responses from a range of responders with different
roles and sites with different recruitment performance
increased the breadth of data gathered in terms of re-
cruitment experience and perspectives, increasing the
precision and generalisability of the results. A high re-
sponse rate from the PIs and at least one research
nurse from each site ensured equal representation of
sites in overall responses, thereby ensuring generalis-
ability and avoiding selection and non-respondent bias.
The study has some potential limitations. The sur-
vey questionnaire has the disadvantage of respondent
non-response, misinterpretation of questions or select-
ive responder bias. To overcome these limitations, the
survey questionnaire was worded in a simple and
clear language and piloted prior to use. The non-
responders were sent frequent email reminders.
The overall response rate was low, though we ob-
tained a good response rate from the PIs and research
nurses. The denominator included all contacts whose
email addresses were available from the delegation
logs; thus, it is likely that not all contacts would have
received the survey if their email addresses had chan-
ged and were different at the time the survey was
conducted. There was a high likelihood of people
changing jobs or rotating between different NHS trusts
during the 2-year duration of the trial, particularly
doctors in training, nursing staff and other junior doc-
tors, resulting in a change in their email addresses and
contact details. This was pre-empted during the plan-
ning stage of this study, and extra efforts were made
to receive a response from the PI and at least one re-
search nurse per site.
The results of the survey are based on subjective expe-
riences of clinical staff responding to the survey ques-
tionnaire and descriptive analysis of responses. We tried
to overcome this limitation by achieving a good repre-
sentation of sites in overall responses and analysing the
PI and at least one research nurse response at each site
separately. This study presents the recruitment experi-
ence of the clinical teams recruiting to the trial. Under-
standing the perspective of other stakeholders such as
parents, young people and families is also very
important.
Conclusions
This study explored the recruitment experience of
various clinical teams recruiting to the MAGNETIC
trial and identified important facilitators and barriers
and information on strategies adopted by clinical
teams to boost recruitment. The findings of the study
can be generalised to other trials, particularly in the
acute/emergency setting, as the study helped to iden-
tify both generic and trial-specific facilitators and bar-
riers to recruitment and can be used to inform the
design and conduct of future clinical trials.
The importance of having motivated and enthusias-
tic clinical teams, good communication skills and a
positive research culture is emphasised. We recom-
mend trialists to consider using study designs with
simpler protocols that are comparable to routine clin-
ical practice, with less restrictive inclusion criteria
and less excessive data collection. Designated research
nurses should be made available at sites to assist clin-
ical staff with recruitment, particularly out of hours.
This is particularly applicable to trials in the acute or
emergency setting with heavy clinical workloads. The
option of deferred consent should be considered for
trials in the emergency setting. Clinical staff should
be encouraged to undertake GCP training, and efforts
should be made to motivate doctors and nursing staff
to participate in research. Adequate training should
be provided to doctors to enhance their confidence
and skills in communicating with parents and fam-
ilies, seeking informed consent and allaying their con-
cerns about the trial or experimental medicine.
Patient information leaflets should be kept short, and
information should be provided in a simple and clear
manner. Trial publicity measures such as posters and
banners should be put up to maintain awareness of
trials among staff and patients. Central trial manage-
ment support should be provided, and efforts should
be made to ensure effective communication between
clinical teams at various sites.
Appendix
Table 5 shows data on overall responses and responses
from PIs and research nurses on facilitators and barriers to
recruitment.
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Table 5 Presentation of the recruitment survey questionnaire used to collect data on facilitators and barriers to recruitment to the
MAGNETIC trial
Factor Facilitator, n (%) Not applicable, n (%) Barrier, n (%)
O PI RN O PI RN O PI RN
Funding 55 (33.0) 14 (43.8) 13 (43.3) 88 (52.7) 13 (40.6) 9 (30.0) 24 (14.4) 5 (15.6) 8 (26.7)
Trial design 71 (42.5) 12 (37.5) 13 (43.3) 33 (19.8) 5 (15.6) 5 (16.7) 63 (37.8) 15 (46.9) 12 (40.0)
Patient inclusion criteria 96 (57.5) 20 (64.5) 20 (66.7) 25 (15.0) 4 (12.9) 3 (10.0) 46 (27.6) 7 (22.6) 7 (23.3)
MAGNETIC being a drug trial 50 (30.0) 10 (31.3) 6 (20.7) 49 (29.3) 17 (53.1) 5 (17.2) 68 (40.7) 5 (15.6) 18 (62.1)
Study protocol compared to clinical practice 61 (36.6) 13 (40.6) 12 (40.0) 28 (16.8) 9 (28.1) 1 (3.3) 78 (46.7) 10 (31.3) 17 (56.7)
Clinical equipoise 69 (42.8) 13 (41.9) 16 (53.3) 72 (44.7) 16 (51.6) 10 (33.3) 20 (12.4) 2 (6.5) 4 (13.3)
Previous feasibility assessment 51 (31.3) 9 (28.1) 11 (39.3) 99 (60.7) 20 (62.5) 15 (53.6) 13 (8.0) 3 (9.4) 2 (7.1)
Previous pilot trial 52 (32.1) 10 (32.3) 11 (39.3) 104 (64.2) 19 (61.3) 16 (57.1) 6 (3.7) 2 (6.5) 1 (3.6)
Publicity by the trial team 103 (62.9) 19 (59.4) 22 (75.9) 43 (26.2) 12 (37.5) 1 (3.4) 18 (10.9) 1 (3.1) 6 (20.7)
External publicity 36 (21.8) 6 (18.8) 6 (20.7) 110 (66.7) 24 (75.0) 17 (58.6) 19 (11.6) 2 (6.3) 6 (20.7)
Trial management 101 (62.0) 19 (59.4) 24 (82.8) 42 (25.8) 9 (28.1) 2 (6.9) 20 (12.3) 4 (12.5) 3 (10.3)
Protocol amendments 49 (29.5) 5 (15.6) 12 (40.0) 90 (54.2) 20 (62.5) 14 (46.7) 27 (16.3) 7 (21.9) 4 (13.3)
Seasonal variation 40 (24.0) 4 (12.5) 10 (33.3) 40 (24.1) 8 (25.0) 2 (6.7) 86 (51.8) 20 (62.5) 18 (60.0)
Site-level factors
Time to open up site 33 (20.0) 5 (15.6) 6 (20.0) 75 (45.5) 9 (28.1) 11 (36.7) 57 (34.5) 18 (56.3) 13 (43.3)
Recruitment target 62 (37.8) 11 (34.4) 13 (46.4) 59 (36.0) 12 (37.5) 9 (32.1) 43 (26.2) 9 (28.1) 6 (21.4)
Time to complete administrative work related to the
trial
24 (14.3) 3 (9.4) 7 (23.3) 32 (19.0) 9 (28.1) 5 (16.7) 112 (66.6) 20 (62.5) 18 (60.0)
Number of trained staff 26 (15.5) 4 (12.5) 3 (10.0) 12 (7.1) 2 (6.3) 2 (6.7) 130 (77.3) 26 (81.3) 25 (83.3)
Local clinical arrangements 43 (26.1) 7 (22.6) 6 (20.0) 36 (21.8) 7 (22.6) 3 (10.0) 86 (52.1) 17 (54.8) 21 (70.0)
Choice of recruitment setting 72 (43.9) 12 (37.5) 13 (43.3) 39 (23.8) 9 (28.1) 2 (6.7) 53 (32.3) 11 (34.4) 15 (50.0)
Good Clinical Practice (GCP) training 33 (19.8) 2 (6.3) 4 (13.3) 18 (10.8) 3 (9.4) 0 (0) 116 (69.6) 27 (84.4) 26 (86.7)
Data collection process 44 (26.5) 10 (31.3) 6 (20.0) 44 (26.5) 14 (43.8) 4 (13.3) 78 (47.0) 8 (25.0) 20 (66.7)
Competing local research projects 23 (13.8) 2 (6.3) 3 (10.0) 116 (69.5) 25 (78.1) 19 (63.3) 28 (16.8) 5 (15.6) 8 (26.7)
Local research culture 65 (39.2) 13 (40.6) 7 (23.2) 32 (19.3) 7 (21.9) 1 (3.3) 69 (41.6) 12 (37.5) 22 (73.3)
Patient factors
Consent rate 48 (29.1) 6 (18.8) 8 (26.7) 39 (23.6) 11 (34.4) 5 (16.7) 78 (47.2) 15 (46.9) 17 (56.7)
Familiarity with experimental treatment 52 (31.3) 7 (21.9) 7 (23.3) 44 (26.5) 13 (40.6) 5 (16.7) 70 (42.1) 12 (37.5) 18 (60.0)
Parent's attitude towards their child taking
experimental medicine or placebo
26 (15.6) 3 (9.4) 5 (17.2) 45 (27.1) 15 (46.9) 6 (20.7) 95 (57.2) 14 (43.8) 18 (62.1)
Parent's preference for a particular treatment 16 (9.6) 0 (0.0) 3 (10.0) 92 (55.4) 26 (81.3) 14 (46.7) 58 (34.9) 6 (18.8) 13 (43.3)
Parent's concerns about side effects of new drug 12 (7.2) 1 (3.1) 1 (3.3) 46 (27.5) 16 (50.0) 6 (20.0) 109 (65.3) 15 (46.9) 23 (76.7)
Duration of trial and follow-up 59 (35.5) 11 (34.4) 12 (41.4) 62 (37.3) 17 (53.1) 7 (24.1) 45 (27.1) 4 (12.5) 10 (34.5)
Treatment choice by random allocation 42 (25.2) 7 (21.9) 7 (23.3) 80 (47.9) 21 (65.6) 13 (43.3) 45 (27.1) 4 (12.5) 10 (33.3)
Additional trial investigations 15 (9.1) 3 (9.4) 2 (6.7) 111 (67.3) 26 (81.3) 17 (56.7) 39 (23.6) 3 (9.4) 11 (36.7)
Additional travel and extra costs 9 (5.4) 3 (9.4) 2 (6.7) 146 (88) 27 (84.4) 27 (90.0) 11 (6.6) 2 (6.3) 1 (3.3)
Intervention available only in the trial 34 (20.5) 5 (15.6) 10 (33.3) 108 (65.1) 25 (78.1) 16 (53.3) 24 (14.4) 2(6.3) 4 (13.3)
Communication between research team and parents 83 (50.1) 11 (34.4) 21 (70.0) 55 (33.1) 19 (59.4) 3 (10.0) 28 (16.8) 2(6.3) 6 (20.0)
Clinician influence 73 (44.0) 9 (28.1) 14 (46.7) 67 (40.4) 19 (59.4) 8 (26.7) 26 (15.6) 4 (12.5) 8 (26.7)
Language or cultural barriers 11 (6.1) 1 (3.1) 1 (3.3) 72 (43.1) 20 (62.5) 13 (43.3) 84 (50.3) 11 (34.4) 16 (53.3)
Clinical team factors
Research experience of clinical team 71 (42.6) 17 (53.1) 6 (20.0) 16 (9.6) 3 (9.4) 1 (3.3) 80 (47.9) 12 (37.5) 23 (76.7)
Presence of designated research nurse/practitioner 113 (68.1) 22 (68.8) 19 (65.5) 17 (10.2) 2 (6.3) 2 (6.9) 36 (21.6) 8 (25.0) 8 (27.6)
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Additional file
Additional file 1: Presents the recruitment survey questionnaire that
was used to gather information on facilitators and barriers and strategies
applied to boost recruitment. (DOCX 55 kb)
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Table 5 Presentation of the recruitment survey questionnaire used to collect data on facilitators and barriers to recruitment to the
MAGNETIC trial (Continued)
Availability of designated research team 97 (58.5) 21 (65.6) 18 (60.0) 24 (14.5) 5 (15.6) 0 (0) 45 (27.0) 6 (18.8) 12 (40.0)
Availability of research staff out of hours 30 (18) 5 (15.6) 6 (20.0) 42 (25.1) 8 (25.0) 5 (16.7) 95 (57.0) 19 (59.4) 19 (63.3)
Shift patterns of work 15 (9) 3 (9.4) 1 (3.3) 22 (13.3) 2 (6.3) 4 (13.3) 129 (77.7) 27 (84.4) 25 (83.3)
Motivation of clinical team 89 (53.6) 16 (50.0) 12 (40.0) 14 (8.4) 4 (12.5) 1 (3.3) 63 (37.9) 12 (37.5) 17 (56.7)
Clinical workload 11 (6.6) 2 (6.3) 1 (3.3) 10 (6.0) 2 (6.3) 1 (3.3) 146 (87.3) 28 (87.5) 28 (93.3)
Perceived importance of research generally in
clinical practice
76 (45.8) 14 (43.8) 8 (26.7) 24 (14.5) 3 (9.4) 3 (10.0) 66 (39.8) 15 (46.9) 19 (63.3)
Perceived importance of the particular research
question
99 (60.1) 20 (62.5) 16 (53.3) 34 (20.6) 6 (18.8) 6 (20.0) 32 (19.4) 6 (18.8) 8 (26.7)
Communication skills of clinical team 116 (70.3) 24 (75) 19 (63.3) 26 (15.8) 7 (21.9) 2 (6.7) 23 (13.9) 1 (3.1) 9 (30.0)
Clinician preference for particular treatment 36 (22.0) 5 (16.1) 7 (24.1) 110 (67.5) 23 (74.2) 19 (65.5) 17 (10.4) 3 (9.7) 3 10.3)
Clinician attitude to involving patients in research 101 (60.9) 18 (56.3) 18 (60.0) 35 (21.1) 9 (28.1) 5 (16.7) 30 (18.0) 5 (15.6) 7 (23.3)
Difficulty in approaching patients for consent 16 (9.6) 3 (9.4) 4 (13.3) 61 (36.5) 16 (50.0) 11 (36.7) 90 (53.9) 13 (40.6) 15 (50.0)
Information and consent-related factors
Amount and complexity of trial information provided 53 (31.9) 10 (31.3) 11 (36.7) 30 (18.1) 11 (34.4) 2 (6.7) 83 (50.0) 11 (34.4) 17 (56.7)
Clarity in presentation of trial information 97 (58.4) 19 (59.4) 20 (66.7) 25 (15.1) 8 (25.0) 2 (6.7) 44 (26.5) 5 (15.6) 8 (26.7)
Social and emotional dynamics of trial discussion 35 (21.0) 7 (21.9) 10 (33.3) 78 (47.0) 20 (62.5) 8 (26.7) 53 (31.9) 5 (15.6) 12 (40.0)
Time and setting of consent seeking 18 (10.8) 2 (6.3) 4 (13.3) 22 (13.2) 4 (12.5) 3 (10.0) 127 (76.0) 26 (81.3) 23 (76.7)
Senior doctors and nurses seeking consent 75 (45.3) 8 (25.8) 16 (53.3) 25 (15.1) 5 (16.1) 2 (6.7) 66 (39.8) 18 (58.1) 12 (40.0)
Experience and training of clinical team seeking
consent
84 (50.4) 12 (37.5) 16 (53.3) 27 (16.2) 8 (25.0) 0 (0) 56 (33.6) 12 (37.5) 14 (46.7)
Study team factors
Motivation of MAGNETIC study team at site 131 (78.9) 25 (80.6) 22 (73.3) 14 (8.4) 3 (9.7) 1 (3.3) 21 (12.6) 3 (9.7) 7 (23.3)
Communication and coordination between study
team members at site
123 (74.5) 24 (77.4) 22 (73.3) 25 (15.2) 6 (19.4) 2 (6.7) 17 (10.2) 1 (3.2) 6 (20.0)
Communication and coordination between study
team at site and CTU
103 (62.1) 19 (61.3) 27 (90.0) 49 (29.5) 9 (29) 3 (10.0) 14 (8.4) 3 (9.7) 0 (0)
Research experience of PI and study team members
at site
105 (63.3) 19 (61.3) 21 (70.0) 38 (22.9) 7 (22.6) 3 (10.0) 23 (13.8) 5 (16.1) 6 (20.0)
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Ethics approval and consent to participate
The project details were sent to the queries line at the National Research
Ethics Service (NRES), and they confirmed that ethical approval was not
needed for this project, as per the ‘Defining Research’ guidance issued by
the NHS National Patient Safety Agency.
We wrote to the potential responders describing the aims of the survey and
provided a link for completion of the online survey. Voluntary participation was
requested, and the potential responders were reassured that no personal
information would be collected, no sites would be identified in any publication
and confidentiality of data would be maintained.
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